share_log

シンバイオ製薬---BCVのPOC確立により2025年に複数の臨床試験を開始し、開発を加速

Synbio Pharmaceutical---With the establishment of POC for BCV, multiple clinical trials will begin in 2025 and development will be accelerated

Fisco Japan ·  May 30 11:03

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment